molecules of the month


mechanism-based SAE E1 ligase inhibitor

first-in-class, Ph. II (IV) for adv. solid tumors

from phenotypic screen and scaffold hop

J. Med. Chem., Feb. 25, 2021

Millenium/Takeda, Cambridge, MA

Chemical structure of molecule TAK-981 Subasumstat
1 min read

5. The Millenium/Takeda SUMO-activating enzyme (SAE) inhibitor TAK-981 is a mechanism-based inhibitor that covalently forms a SUMO substrate-inhibitor adduct that potently inhibits SAE, rather than reacting with SAE directly. The Takeda team has been able to successfully leverage this fascinating mechanism to develop potent inhibitors against a range of E1 enzymes including ATG7 and NEDD8-activating enzyme (NAE), one of which (pevonedistat) is currently in a Ph. III trial for AML. TAK-981 is currently in combination Ph. II trials for advanced solid tumors as an intravenous infusion. This Takeda platform is another great example of how chasing down mechanisms from a phenotypic screen can lead to a rich pipeline of new targets and clinical candidates beyond what was originally intended.

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: